CHINARES PHARMA (03320) subsidiary completes issuance of RMB900 million corporate bonds.

CHINARES PHARMA (03320) announced that its wholly-owned subsidiary, CHINARES PHARMA Holdings Limited (CHINARES PHARMA Holdings), has completed the public issuance in China of the second tranche of its 2026 corporate bonds. The second tranche of the 2026 corporate bonds, with a principal amount of RMB900 million, has been issued with a term of three years and a coupon rate of 1.48% per annum. The net proceeds from the issuance of the second tranche of the 2026 corporate bonds will be used for productive expenditures, including repayment of the company's debts, replenishment of working capital, project development and operating expenditures, investments related to technological innovation, and other purposes in compliance with applicable laws and regulations.